drugset
Drugs / INT-787
last change Feb 2026 re-read 3 minutes ago

INT-787

Developed for
alcoholic hepatitis

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT05639543 Comparator Dec 2022 → Feb 2026 alcoholic hepatitis Intercept Pharmaceuticals Terminated No outcome recorded Stop: Business

Press releases naming this drug 1 release

DateIssuerRelease
2022-11-08 Tes Pharma S.r.l. TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis tespharma.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as INT-787 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639543 ↗